Expanding Diagnostics Adarza’s AIR technology enables multiplexed detection across hundreds of analytes with high sensitivity and specificity, spanning discovery to clinic. This positions the company to pursue collaborations with biopharma and diagnostics developers seeking scalable, label-free assays for companion diagnostics and biomarker panels.

Clinical Pipeline Fit The platform is described as the only solution that covers the entire companion diagnostic life cycle and supports high-throughput core facilities as well as point of care settings, presenting sales opportunities to CROs, clinical labs, and hospital systems aiming for versatile assay deployment.

Strategic Partnerships Recent fundraising history (Series B through Series D) and news of platform launches like ZIVA indicate growth momentum and investor confidence, suggesting opportunities to engage strategic partners for co-development, licensing, or manufacturing scale to accelerate market reach.

Operational Footprint With facilities expansion and a distributed presence in St. Louis and Fallon, NV, Adarza may benefit from sales outreach focusing on regional biotech clusters, contract manufacturers, and research centers seeking local support and shorter supply chains.

Market Position As a niche player in label-free multiplex biosensor assays with a focus on proteomics research, Adarza can target mid-market biotechs and academic labs seeking high multiplexing capability, quick ROI, and integration with existing laboratory infrastructure using familiar tech stacks.